| Document |
Document Title |
|
WO/2023/165382A1 |
The present invention provides an acyltadine compound having α-glycosidase and/or β-glycosidase inhibitory activity and a preparation method, and use of the α-glycosidase and/or β-glycosidase inhibitor in preventing and treating dise...
|
|
WO/2023/165062A1 |
Provided are a method for preparing oligodendrocytes and use. According to the solution provided, the major steps of oligodendrocyte differentiation is replayed in a time significantly shorter than 75-95 days which are required for previ...
|
|
WO/2023/166356A1 |
The protein concentrate of orange seed was hydrolyzed using the digestive enzyme alcalase at a temperature of 50 C° and a pH of 8 for 3.5 hours in sugar-coated incubators, and after a specified period of time, the enzyme used at a tempe...
|
|
WO/2023/166540A1 |
The present disclosure provides novel milk and dark chocolate compositions fortified with olive leaf extract including at least cocoa mass, cocoa butter, emulsifier, sweetener, and flavoring agent to produce solid chocolate bars with hig...
|
|
WO/2023/168240A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2023/166069A1 |
The invention relates to a first composition providing at least one of acetic acid or butyric acid for controlling ketosis associated with a ketogenic diet in a subject adhering to a ketogenic diet, wherein controlling ketosis involves a...
|
|
WO/2023/165856A1 |
The present invention generally relates to the use of a composition comprising mulberry leaf extract, a source of fiber and a source of unsaturated fatty acids to decrease postprandial glucose (PPG) response. More particularly, it relate...
|
|
WO/2023/165094A1 |
Disclosed in the present application are a hydroxypentyl benzoic acid diester compound, and a preparation method therefor and the use thereof. The principle of combination is used in the present application. On the one hand, the drug con...
|
|
WO/2023/165168A1 |
The present invention relates to an application of a pyrazole derivative as a β 2 adrenergic receptor allosteric modulator, antagonist and agonist. An acetophenone or an acetophenone containing different substituents is used as an initi...
|
|
WO/2023/166413A1 |
The present invention relates to a composition of substances, preferably obtained from natural sources, effective in the prevention and/or treatment of hypercholesterolemia. The invention composition comprises an extract of red yeast ric...
|
|
WO/2023/168367A1 |
The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
|
|
WO/2023/166074A1 |
The invention relates to at least one of C4 or C6 fatty acids and optionally C2 fatty acids for enhancing ketosis associated with a ketogenic diet and/or preventing and/or treating resistance to a ketogenic diet, in a subject adhering to...
|
|
WO/2023/167336A1 |
This pharmaceutical composition for treatment or prevention of fibrotic disease contains nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consistin...
|
|
WO/2023/167340A1 |
The present invention relates to a chimeric peptide containing a first domain and a second domain, wherein the first domain contains (i) a peptide containing at least an amino acid sequence shown by any of ID SEQ NOS: 1-4, (ii) a peptide...
|
|
WO/2023/164752A1 |
The present invention is a method of preparation of standardized ethanolic and aqueous plant extract powder from Ilex paraguariensis leaves for human or veterinary use. The present invention also provides the identification of compounds ...
|
|
WO/2023/164050A1 |
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...
|
|
WO/2023/160405A1 |
Provided is a compound NMNH disodium salt, and the present invention in particular relates to a polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutica...
|
|
WO/2023/164358A1 |
The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.
|
|
WO/2023/163140A1 |
The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
|
|
WO/2023/163170A1 |
The embolic agent according to the present invention is a copolymer formed from a cationic functional group-containing monomer and an aromatic group-containing monomer, said embolic agent having, as an active ingredient, a copolymer whic...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/160700A1 |
Provided herein are compositions and methods for treating cardiovasculardisease, particularly those known to be caused by endothelial dysfunctions due to nitricoxide (NO) deficiency in patients.The colloidal coordination compounds, inclu...
|
|
WO/2023/164431A1 |
Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac el...
|
|
WO/2023/159601A1 |
USE of an agent that deacetylates a transcription factor KLF4 to promote a transcriptional activity thereof in preparation of a medicament for treating pulmonary arterial hypertension is provided. The agent is configured to deacetylate t...
|
|
WO/2023/161227A1 |
The present invention relates to a complex coacervate comprising lactoferrin and osteopontin, processes of producing the same and composition comprising the same. Moreover, the present invention relates to complexes comprising lactoferri...
|
|
WO/2023/163521A1 |
The present invention relates to a DNA aptamer specifically binding to LDL, and a use of the DNA aptamer. Specifically, the DNA aptamer, according to the present invention, specifically binds to LDL with high affinity and inhibits LDL wh...
|
|
WO/2023/160344A1 |
Disclosed are a NO donor compound, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof. The structure of the compound is represented by formula I. The NO donor compound and the pharmaceutical comp...
|
|
WO/2023/163596A1 |
The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment or prophylaxis of aging, or idiopathic ageing-associated disorders such as vascular ageing or reduced renal function. Spe...
|
|
WO/2023/164440A1 |
Provided herein are cell and protein therapeutics that comprise a Proteinase 3 (PR3) antibody binding domain, such as a wild type PR3 protein or mutant PR3 protein, and methods of use thereof. Also provided herein are chimeric autoantibo...
|
|
WO/2023/158159A1 |
The present invention relates to a nanodisc comprising angiotensin converting enzyme 2 (ACE2) and a membrane scaffold protein (MSP). In the present invention, the angiotensin converting enzyme 2 (ACE2) is included in the nanodisc, and it...
|
|
WO/2023/158634A1 |
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatm...
|
|
WO/2023/156768A1 |
The present disclosure provides compositions which may be useful in the generation of vitamin D and/or nitric oxide, in particular when exposed to radiation (e.g. light and/or UV radiation). The disclosure further provides methods of gen...
|
|
WO/2023/155873A1 |
The present application provides a carboxylic acid compound, a method for preparing same, and use thereof in pharmaceutics. Specifically, the present application provides a carboxylic acid compound represented by formula (I), a method fo...
|
|
WO/2023/155900A1 |
Provided in the present invention are a preparation and use of a five-membered and six-membered heterocyclic compound, and particularly provided is a compound as shown in the following formula I, wherein the definition of each group is a...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/158681A1 |
Methods, uses, and kits are provided for treating a subject having impaired perfusion by administering an extended delivery regimen of a blood cell growth factor to stimulate fibrinolysis and/or neovascularization. The methods, uses, and...
|
|
WO/2023/156911A1 |
The present disclosure provides pharmaceutical compositions comprising thiotepa, water, one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally thiosulfate or such compositions which is free or substantially free of imp...
|
|
WO/2023/159150A1 |
Disclosed herein include methods for preventing, inhibiting, reducing, or treating cardiac ischemic injury. The method comprises administering a therapeutic composition comprising a plurality of microRNA (miR) antagonists to a subject be...
|
|
WO/2023/152500A1 |
The present disclosure relates to the technical field of medicaments. Particularly, the present disclosure provides a pharmaceutical combination/composition comprising a phosphodiesterase type 5 (PD1 5) inhibitor, arginine, and N-acetyle...
|
|
WO/2023/154705A1 |
The disclosure relates to treatment of a disease, such as pulmonary hypertension, by inhalation with a combination of iloprost and treprostinil.
|
|
WO/2023/154850A2 |
Fragile X Mental Retardation protein (FMRP) is an RNA-binding protein (RBP) that controls translation of select mRNAs. We discovered that endoplasmic reticulum (ER) stress induces phosphorylation of FMRP on a site that is known to enhanc...
|
|
WO/2023/153902A1 |
The present invention relates to a composition for inhibiting preadipocyte differentiation and lipid accumulation, comprising Enterococcus faecalis as an active ingredient. Particularly, it was confirmed that killed E. faecalis EF-2001 i...
|
|
WO/2023/154014A1 |
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....
|
|
WO/2023/154499A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2023/152698A1 |
The present invention relates to compounds of formula (I): as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperg...
|
|
WO/2023/154479A1 |
The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant...
|
|
WO/2023/154933A1 |
Treatments and methods for inhibiting late Na current use fibroblast growth factor homologous factor (FHF), an endogenous channel modulator, to inhibit late Na current with high potency. A minimal effector domain is engineered within FHF...
|
|
WO/2023/154923A2 |
The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of tr...
|
|
WO/2023/152761A1 |
The present invention relates to crystalline rosuvastatin allyl ester (1), to a process for its manufacture, to pharmaceutical compositions comprising it as well as the use of crystalline (1 ) in medicine. The medicine can be useful, for...
|
|
WO/2022/174116A9 |
The disclosure relates to methods of producing nitric oxide (NO) gas that is administrable without specialized equipment and does not provide nitrogen dioxide (NO2) gas. The methods comprise combining a nitrate and/or nitrite anion and a...
|
